No­var­tis takes an­oth­er step for­ward in glob­al Kym­ri­ah roll­out as Japan OKs the drug at $305K

No­var­tis has won an ap­proval to sell its land­mark CAR-T ther­a­py Kym­ri­ah in Japan at a dis­count price as it con­tin­ues its slow roll­out around the globe while it grad­u­al­ly builds up its man­u­fac­tur­ing op­er­a­tions.

Japan’s Cen­tral So­cial In­sur­ance Med­ical Coun­cil of­fered No­var­tis a shot at of­fer­ing the drug to an es­ti­mat­ed 216 new can­cer pa­tients a year suf­fer­ing from acute lym­phoblas­tic leukemia and adult pa­tients with dif­fuse large B-cell lym­phoma.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER